Prothena Corporation (PRTA) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- -$0.31
- Estimate
- -$0.30
- Surprise
- -4.3%
- Revenue (period 2026-09-30)
- $620,000
- Score today
- 5.1/10
Revenue source: xbrl.
How the report landed
Prothena Corporation (PRTA) reported a wider loss than forecast — adjusted EPS of -$0.31 against the -$0.30 estimate (a 4.3% shortfall).
Coverage in the report window
- Prothena Reports Third Quarter 2026 Financial Results and Business Highlights — fiscal.ai, 2026-11-05
- Prothena Corp Q3 EPS $(0.32), Inline, Sales $620.000K — benzinga, 2026-11-05
Where TrendMatrix's rating stands now
TrendMatrix currently rates PRTA Sell at 5.1/10; no pre/post engine snapshot brackets this report.
2 of the last 4 quarters beat the estimate; this quarter's -4.3% surprise compares with a +84.7% four-quarter average. Next scheduled report: 2027-02-18.
What argues against it
- Quality below floor (1.8 < 4.0)
- Momentum score 2.4/10 — below 4.5 minimum
- Death cross — 50-day MA below 200-day MA
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $7.97
- Price target
- $18.62
- Stop
- $7.63
- Upside to target
- +133.6%
- Reward-to-risk
- 12.9:1
Model outputs from TrendMatrix’s engine as of 2026-11-07 — shown for context, not personalized investment advice.
PRTA at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $409.2M
- P/E (fwd)
- -6.1
- 52-week range
- $7.73–$11.80
- Off 52-week high
- 32.5%
- RSI (14)
- 42
- Volume vs avg
- 0.88×
- Score today
- 5.1/10